SCHEMBL337983

SCHEMBL337983

Cn1c(-c2ccccc2)nc2cc(Br)ccc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.58
RAB9A P51151 4/20 0.58
TP53 P04637 4/20 0.58
NPC1 O15118 3/20 0.58
ALOX15 P16050 3/20 0.58
MAPT P10636 3/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
TSHR P16473 1/20 0.58
MAPK1 P28482 1/20 0.58
HDAC1 Q13547 1/20 0.58
HDAC8 Q9BY41 1/20 0.58
HDAC6 Q9UBN7 1/20 0.58
ATM Q13315 2/20 0.56
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
PDE10A Q9Y233 1/20 0.51
PKM P14618 3/20 0.50
KDM4E B2RXH2 3/20 0.50
HSD17B10 Q99714 3/20 0.50
GAA P10253 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20982735 0.92 ALDH1A1 (0.63) ALDH1A1RAB9ATP53NPC1ALOX15
SCHEMBL20982762 0.87 ATM (0.53) ALDH1A1RAB9ATP53NPC1ALOX15
SCHEMBL17896623 0.86 MEN1 (0.62) ALDH1A1RAB9ATP53NPC1ALOX15
SCHEMBL22439775 0.85 ALDH1A1 (0.60) ALDH1A1RAB9ATP53NPC1ALOX15
SCHEMBL26603103 0.84 ALDH1A1 (0.56) ALDH1A1RAB9ATP53NPC1ALOX15
SCHEMBL30663908 0.84 ALDH1A1 (0.56) ALDH1A1RAB9ATP53NPC1ALOX15
SCHEMBL14075995 0.84 ALDH1A1 (0.56) ALDH1A1RAB9ATP53NPC1ALOX15
SCHEMBL26603063 0.84 MAPT (0.52) ALDH1A1RAB9ATP53NPC1ALOX15
SCHEMBL30663909 0.84 MAPT (0.52) ALDH1A1RAB9ATP53NPC1ALOX15
SCHEMBL10175606 0.84 CYP11B2 (0.60) ALDH1A1RAB9ATP53NPC1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250339494-A1 COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS UNIV PARIS CITE (FR) 2025-11-06 US claimed
EP-4511022-A1 COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS Université Paris Cité (FR) 2025-02-26 EP claimed
WO-2023203162-A1 COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS UNIVERSITE PARIS CITE (FR) 2023-10-26 WO claimed
EP-4265247-A1 COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS Université Paris Cité (FR) 2023-10-25 EP claimed
CN-108689945-A Preparation method of benzimidazole derivative 江苏理工学院 2018-10-23 CN claimed
EP-2188282-A2 1,2-DIAMIDO-ETHYLENE DERIVATIVES AS OREXIN ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2010-05-26 EP claimed
WO-2009022311-A2 1,2-DIAMIDO-ETHYLENE DERIVATIVES AS OREXIN ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2009-02-19 WO claimed
US-20250339494-A1 COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS UNIV PARIS CITE (FR) 2025-11-06 US disclosed
EP-1602648-B2 Nitrogen-containing heterocycle derivative and organic electroluminescent element using the same IDEMITSU KOSAN CO (JP) 2025-03-26 EP disclosed
EP-4511022-A1 COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS Université Paris Cité (FR) 2025-02-26 EP disclosed
WO-2023203162-A1 COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS UNIVERSITE PARIS CITE (FR) 2023-10-26 WO disclosed
WO-2023203162-A1 COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS UNIVERSITE PARIS CITE (FR) 2023-10-26 WO disclosed
EP-4265247-A1 COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS Université Paris Cité (FR) 2023-10-25 EP disclosed
WO-2007061737-A2 FUSED BICYCLIC mTOR INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2007-05-31 WO disclosed
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer OSI PHARMACEUTICALS, INC. 2007-05-17 US disclosed
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer OSI PHARMACEUTICALS, INC. 2007-05-17 US disclosed
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer OSI PHARMACEUTICALS, INC. 2007-05-17 US disclosed
EP-1734038-A1 NITROGENOUS HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2006-12-20 EP disclosed
US-20060147747-A1 2-[4-(10-naphthalene-2-yl-anthracene-9-yl)-phenyl]-1-phenyl-1H-benzimidazole; elevation of luminance and of efficiency in light emission even under low driving voltage IDEMITSU KOSAN CO., LTD. (JP) 2006-07-06 US disclosed
EP-1602648-A1 NITROGEN-CONTAINING HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2005-12-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250339494-A1 COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS IL2, CXCL10, IFNG ALDH1A1 2221/4885RAB9A 1672/4885TP53 2308/4885
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer MTOR, MAPKAP1, RPS6KA1 ALDH1A1 4496/4885RAB9A 1191/4885TP53 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.